---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-021189"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:49:30.545435+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acumen reports FY2025 net loss $121.3M; cash $116.9M; ALTITUDE-AD topline due late 2026

## Summary
- Net loss $121.3M for FY2025 ($102.3M in FY2024); R&D expenses rose to $104.9M.
- Cash, equivalents and marketable securities $116.9M as of Dec 31, 2025; expected to fund operations into early 2027.
- Phase 2 ALTITUDE-AD (sabirnetug) topline results expected late 2026; OLE dosing commenced Nov 2025.
- $35.75M private placement closed March 2026 to advance Enhanced Brain Delivery (EBD) program; IND filing targeted mid-2027.
- EBD program candidates showed up to 40-fold brain exposure in NHPs; low anemia risk; subcutaneous potential.

## SEC filing metadata
- accession: 0001628280-26-021189
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/0001628280-26-021189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/abos-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-021189
- JSON: https://secwatch.observer/filing/0001628280-26-021189.json
- Plain text: https://secwatch.observer/filing/0001628280-26-021189.txt

## Key facts
- Earnings Releases
  Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2025 results: net income Net loss was $121.3 million.
  - Period: the year ended December 31, 2025
  - Net income: Net loss was $121.3 million
  - Result: reported results
  source text: Net loss was $121.3 million for the year ended Dec. 31, 2025, compared to $102.3 million for the year ended Dec. 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/0001628280-26-021189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.